Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation
Lymphoproliferative Disorder
About this trial
This is an interventional treatment trial for Lymphoproliferative Disorder focused on measuring post-transplant lymphoproliferative disorder
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of post-transplant lymphoproliferative disease (PTLD) after solid organ (heart, heart/lung, liver, liver/gut, pancreas, or kidney) transplantation Epstein-Barr virus-positive tumor Newly diagnosed disease Measurable disease by clinical methods or radiography Must have partially matched donor cytotoxic T cells (CTL) available No known panel reactivity to any of the HLA types of CTL available for therapy PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 20-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior therapy for PTLD No concurrent antiviral drugs (e.g., acyclovir or ganciclovir) for PTLD
Sites / Locations
- Birmingham Children's Hospital
- Papworth Hospital
- Royal Free and University College Medical School
- King's College Hospital
- Wythenshawe Hospital
- Central Manchester and Manchester Children's University Hospitals NHS Trust
- Northern General Hospital
- Institute of Cancer Research - UK
- Royal Infirmary of Edinburgh at Little France
- University of Edinburgh
- University of Edinburgh Laboratory for Clinical and Molecular Virology
- Royal Infirmary - Castle